MDNA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 23.68%

Insider Buying (Last 12 Months): C$0.00

Insider Selling (Last 12 Months): C$0.00

Medicenna Therapeutics Insider Trading History Chart

Medicenna Therapeutics Share Price & Price History

C^$1.55

▲ +0.02 (1.31%)

As of 04/23/2024 01:00 AM ET

Days: 30 | 90 | 365

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Medicenna Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/11/2022	Albert George Beraldo	Director	Buy	25,000	C$1.18	C$29,482.50	325,000
10/6/2022	Albert George Beraldo	Director	Buy	5,600	C$1.15	C$6,440.00	295,300
9/29/2022	Chandra Panchal	Director	Buy	1,000	C$0.79	C$790.00	3,000
11/1/2021	Elizabeth Williams	Senior Officer	Buy	4,000	C$2.75	C$10,982.80	10,300

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad

Claim your free seat by clicking here now.

SEC Filings (Institutional Ownership Changes) for Medicenna Therapeutics (TSE:MDNA)

7.86% of Medicenna Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Today's Range

Now: C$1.55

C$1.52

C$1.64

50 Day Range

MA: C$1.45

C$0.66

C$1.96

52 Week Range

Now: C$1.55

C$0.22

C$2.10

Volume

70,982 shs

Average Volume

124,075 shs

Market Capitalization

C$107.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Who are the company insiders with the largest holdings of Medicenna Therapeutics?: Medicenna Therapeutics' top insider investors include:
Albert George Beraldo (Director)
Chandra Panchal (Director)
Learn More about top insider investors at Medicenna Therapeutics.